ViiV Healthcare's innovative portfolio of medicines provides options—because individualising care for people living with HIV matters, to you and to us.
Dovato (dolutegravir/lamivudine) is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.
Vocabria injection in combination with Rekambys injection is indicated for the treatment of HIV-1 in adults and adolescents (at least 12 years of age and weighing at least 35 kg), who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior failure with agents of NNRTI and INI class.
Apretude (cabotegravir) long-acting for PrEP is indicated in combination with safer sex practices, to reduce the risk of sexually acquired HIV-1 in high-risk adults and adolescents, weighing at least 35 kg.
RESOURCES
Resources
View bite-size infographics on the latest studies and data to help inform your HIV practice
PM-GB-HVX-WCNT-220004 May 2025
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
